Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 3/20 | 0.75 |
| ▸ | FNTB | P49356 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.64 |
| ▸ | SQLE | Q14534 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15639481 | 1.00 | FNTA (0.75) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL7884676 | 0.98 | FNTA (0.72) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL16125772 | 0.92 | SQLE (0.70) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL11549064 | 0.92 | FNTA (0.66) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL11549061 | 0.92 | FNTA (0.66) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL16212270 | 0.90 | FNTA (0.61) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL14825967 | 0.90 | FNTA (0.64) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL726071 | 0.89 | KMT2A (0.64) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL726070 | 0.89 | KMT2A (0.64) | FNTAFNTBKMT2AALOX15MAPT | |
| SCHEMBL29255675 | 0.89 | FNTA (0.68) | FNTAFNTBKMT2AALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080089950-A1 | Methods and compositions for modulating the immune system and uses thereof | CHEN LAN B | 2008-04-17 | — | — | US | claimed |
| EP-1563849-A2 | Methods and compositions for modulating the immune system and uses thereof | DANA-FARBER CANCER INSTITUTE (US) | 2005-08-17 | — | — | EP | claimed |
| EP-1455775-A2 | METHODS AND COMPOSITIONS FOR MODULATING THE IMMUNE SYSTEM AND USES THEREOF | DANA-FARBER CANCER INSTITUTE (US) | 2004-09-15 | — | — | EP | claimed |
| US-20040022869-A1 | Methods and compositions for modulating the immune system and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. | 2004-02-05 | — | — | US | claimed |
| WO-2003047524-A2 | METHODS AND COMPOSITIONS FOR MODULATING THE IMMUNE SYSTEM AND USES THEREOF | DANA-FARBER CANCER INSTITUTE (US) | 2003-06-12 | — | — | WO | claimed |
| US-20250215004-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS (DE) | 2025-07-03 | — | — | US | disclosed |
| EP-4559521-A2 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) | 2025-05-28 | — | — | EP | disclosed |
| EP-4404931-B1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN (DE) | 2025-04-09 | — | — | EP | disclosed |
| CN-119233820-A | Azo compounds for the treatment of fibrotic diseases | 乔治-奥古斯特-哥廷根公法基金会大学的大学医学院 | 2024-12-31 | — | — | CN | disclosed |
| US-20230024933-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENLICHEN RECHTS, UNIVERSITAETSMEDIZIN (DE) | 2023-01-26 | — | — | US | disclosed |
| US-11331333-B2 | Treatment of aberrant fibroblast proliferation | Georg-August-Universität Göttingen Stiftung Öffentichen Rechts, Universitätsmadizin (DE) | 2022-05-17 | — | — | US | disclosed |
| US-20210137963-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENLICHEN RECHTS, UNIVERSITAETSMEDIZIN (DE) | 2021-05-13 | — | — | US | disclosed |
| US-20080089950-A1 | Methods and compositions for modulating the immune system and uses thereof | CHEN LAN B | 2008-04-17 | — | — | US | disclosed |
| WO-2008038712-A1 | THERAPEUTIC/PROPHYLACTIC AGENT FOR METABOLIC SYNDROME | KUMAMOTO UNIVERSITY (JP) | 2008-04-03 | — | — | WO | disclosed |
| CN-1791394-A | Preventive and/or therapeutic agent for inflammatory bowel disease | EISAI CO LTD (JP) | 2006-06-21 | — | — | CN | disclosed |
| EP-1563849-A2 | Methods and compositions for modulating the immune system and uses thereof | DANA-FARBER CANCER INSTITUTE (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1455775-A2 | METHODS AND COMPOSITIONS FOR MODULATING THE IMMUNE SYSTEM AND USES THEREOF | DANA-FARBER CANCER INSTITUTE (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040022869-A1 | Methods and compositions for modulating the immune system and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003047524-A2 | METHODS AND COMPOSITIONS FOR MODULATING THE IMMUNE SYSTEM AND USES THEREOF | DANA-FARBER CANCER INSTITUTE (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024933-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | EYA2, EYA3, PTP4A1 | FNTA 2413/4885FNTB 1953/4885KMT2A 702/4885 |
| US-20080089950-A1 | Methods and compositions for modulating the immune system and uses thereof | ICOS, MALT1, LTA | FNTA 2402/4885FNTB 4778/4885KMT2A 1874/4885 |
| US-20210137963-A1 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | EYA2, EYA3, PTP4A1 | FNTA 2413/4885FNTB 1953/4885KMT2A 702/4885 |
| US-11331333-B2 | Treatment of aberrant fibroblast proliferation | EYA2, EYA3, PTP4A1 | FNTA 2413/4885FNTB 1953/4885KMT2A 702/4885 |
| US-20250215004-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | COL1A1, COL14A1, COL2A1 | FNTA 653/4885FNTB 113/4885KMT2A 2716/4885 |
| US-20040022869-A1 | Methods and compositions for modulating the immune system and uses thereof | ICOS, MALT1, LTA | FNTA 2402/4885FNTB 4778/4885KMT2A 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.